This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Cornell University. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Maureen Lane: Innovator in Cancer Prognostics
Introduction
Maureen Lane is a notable inventor based in Mount Vernon, NY (US). She has made significant contributions to the field of cancer research through her innovative work on prognostic indicators for cancer progression and relapse.
Latest Patents
Maureen Lane holds a patent titled "Bone marrow-derived hematopoietic progenitor cells and endothelial progenitor cells as prognostic indicators for cancer." This patent outlines methods for determining cancer progression or relapse in subjects at risk. The methods involve obtaining a sample from the subject, measuring the levels of VEGFR1 hematopoietic progenitor cells (HPCs) and/or VEGFR2 endothelial progenitor cells (EPCs), and conducting additional measurements at later time points. A surge in the levels of HPCs and/or EPCs indicates an increased risk of cancer progression or relapse.
Career Highlights
Maureen Lane is affiliated with Cornell University, where she continues her research and development in cancer prognostics. Her work is pivotal in enhancing the understanding of cancer dynamics and improving patient outcomes.
Collaborations
She collaborates with esteemed colleagues, including Linda Vahdat and Vivek Mittal, to further advance her research initiatives.
Conclusion
Maureen Lane's innovative contributions to cancer research exemplify the impact of scientific inquiry on healthcare. Her patent serves as a valuable tool for predicting cancer progression, ultimately benefiting patients at risk.